Efficacy and Prognosis of Almonertinib and Gefitinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer with EGFR Mutation

ZENG Hanmei; WANG Limin

doi:10.3969/j.issn.1002-3429.2024.10.008

Abstract：Objective To investigate the efficacy and prognosis of Almonertinib and Gefitinib in the treatment of lo-cally advanced non-small cell lung cancer(NSCLC)with epidermal growth factor receptor(EGFR)mutation.Methods A total of 100 patients diagnosed with locally advanced NSCLC with EGFR mutation from March 2019 to September 2022 were selected and divided into group A(n=57)and group B(n=43)according to different treatment methods.Group A was trea-ted with Almonertinib and group B was treated with Gefitinib,both of which were treated for 2 cycles.Objective response rate(ORR),disease control rate(DCR),serum EGFR level,immunoglobulin levels[immunoglobulin M(IgM),immunoglobu-lin A(IgA),immunoglobulin G(IgG)],and incidence of toxic and side effects were compared between the two groups.All patients were followed up for 12 to 42 months,and survival curves were drawn.Median overall survival(OS)and median progression-free survival(PFS)were compared between the two groups.Results ORR and DCR were 28.07%and 77.19%in group A,and 11.63%and 44.19%in group B,respectively,with statistical significance(P＜0.05).After treatment,the serum EGFR levels in group A were lower than those in group B,while the IgM,IgA and IgG levels were higher than those in group B,with statistical significance(P＜0.05).The incidence of grade＜3 and≥3 toxic and side effects were 71.93%and 21.05%respectively in group A,and 48.84%and 41.86%respectively in group B,with statistical significance(P＜0.05).Themedian OS and PFS were16.9 months and5.8 months respectively in group A,and 10.5 months and 4.0 months respectively in group B,showing significant difference(P＜0.05).Conclusion Compared with Gefitinib,Almoner-tinib is more effective in the treatment of patients with locally advanced NSCLC with EGFR mutation,which can better control disease development,improve EGFR level and immune indexes,and improve patient survival rate,and has a certain safety.